0001628280-25-015269 Sample Contracts
WHITEHAWK THERAPEUTICS, INC.Stock Option Agreement • March 28th, 2025 • Whitehawk Therapeutics, Inc. • Pharmaceutical preparations • California
Unless otherwise defined herein, the terms defined in the Whitehawk Therapeutics, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement which includes the Notice of Stock Option Grant, the Terms and Conditions of Stock Option Grant, attached hereto as Exhibit A, and all appendices and exhibits attached thereto (all together, the “Option Agreement”).
AADI BIOSCIENCE, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 28th, 2025 • Whitehawk Therapeutics, Inc. • Pharmaceutical preparations • New Jersey
This Executive Employment Agreement (the “Agreement”) is entered into as of January 24, 2025 by and between Aadi Bioscience, Inc. (“Aadi”), and David Dornan, Ph.D. (“Executive”). This Agreement will be effective February 18, 2025 (the “Effective Date”). Aadi, together with any other subsidiaries, including the entity employing you, shall be referred to in this letter as the “Company”.
WHITEHAWK THERAPEUTICS, INC. RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANTRestricted Stock Unit Agreement • March 28th, 2025 • Whitehawk Therapeutics, Inc. • Pharmaceutical preparations • California
Unless otherwise defined herein, the terms defined in the Whitehawk Therapeutics, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement which includes the Notice of Restricted Stock Unit Grant (the “Notice of Grant”), the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as Exhibit A, the Country Addendum attached hereto as Exhibit B, and all other exhibits, appendices, and addenda attached hereto (together, the “Award Agreement”).
INTELLECTUAL PROPERTY LICENSE AGREEMENT BETWEEN WUXI BIOLOGICS (SHANGHAI FX) CO., LTD. AND AADI BIOSCIENCE, INC.Intellectual Property License Agreement • March 28th, 2025 • Whitehawk Therapeutics, Inc. • Pharmaceutical preparations
THIS INTELLECTUAL PROPERTY LICENSE AGREEMENT (“Agreement”) dated as of December 19, 2024 (“Effective Date”), is entered into between WuXi Biologics (Shanghai FX) Co., Ltd., a corporation organized and existing under the laws of China, having offices at Room 2481, Building No.1,1150 Lan Feng Road, Fengxian District, Shanghai, 201403, China (“WuXi Biologics”) and Aadi Bioscience, Inc., a Delaware corporation having offices at 2 Headquarters Plaza, East Building, 11th Floor, Morristown, NJ 07960 (“Aadi”).